PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 32613602-9 2020 Transwell assay showed safinamide prevented OGD/R-induced hyperpermeability and the reduction of occludin and ZO-1. safinamide 23-33 occludin Mus musculus 97-105 33887441-4 2021 Among the synthesized 31 compounds, K8 and K24 demonstrated very encouraging hMAO-B inhibitory activities and selectivity over hMAO-A, better than rasagiline and safinamide. safinamide 162-172 keratin 24 Homo sapiens 43-46 33387637-6 2021 Nevertheless, evidence from multiple preclinical studies suggested a potent, selective and reversible inhibitory activity of safinamide against monoamine oxidase (MAO)-B enzyme which is responsible for degrading dopamine, a neurotransmitter primarily implicated in the pathophysiology of PD. safinamide 125-135 monoamine oxidase B Homo sapiens 144-169 32613602-7 2020 Results indicate that the administration of safinamide significantly ameliorated MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impaired expression of tight junction protein occludin and ZO-1. safinamide 44-54 tight junction protein 1 Mus musculus 251-255 32613602-8 2020 In cultured brain endothelial cell line bEND.3, pre-treatment with safinamide alleviated oxygen and glucose deprivation/reperfusion (OGD/R) caused cytotoxicity and favored cell survival. safinamide 67-77 BEN domain containing 3 Mus musculus 40-46 34031800-2 2022 Safinamide is a new monoamine oxidase B inhibitor, also exerting a non-dopaminergic effect, recently approved as add-on therapy in fluctuating PD patients. safinamide 0-10 monoamine oxidase B Homo sapiens 20-39 33068177-1 2021 Safinamide is a monoamine-oxidase-B inhibitor with peculiar features. safinamide 0-10 monoamine oxidase B Homo sapiens 16-35 32682215-0 2020 Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein -2(UCP-2). safinamide 49-59 brain derived neurotrophic factor Homo sapiens 139-143 32682215-0 2020 Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein -2(UCP-2). safinamide 49-59 neurotrophic receptor tyrosine kinase 2 Homo sapiens 144-148 32682215-0 2020 Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein -2(UCP-2). safinamide 49-59 PPARG coactivator 1 alpha Homo sapiens 149-159 32682215-0 2020 Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein -2(UCP-2). safinamide 49-59 uncoupling protein 2 Homo sapiens 182-217 32682215-0 2020 Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein -2(UCP-2). safinamide 49-59 uncoupling protein 2 Homo sapiens 218-223 32682215-2 2020 Safinamide is a novel inhibitor of monoamine oxidase B (MAOB) with neuroprotective properties. safinamide 0-10 monoamine oxidase B Homo sapiens 35-54 32682215-2 2020 Safinamide is a novel inhibitor of monoamine oxidase B (MAOB) with neuroprotective properties. safinamide 0-10 monoamine oxidase B Homo sapiens 56-60 32682215-6 2020 Previous studies have shown that safinamide, a monoamine oxidase-B (MAOB) inhibitor, can function as a neuroprotective agent and inhibit the neurodegenerative process especially in Parkinson"s disease but its impact on other neurodegenerative processes and drug-induced neurotoxicity remain unclear. safinamide 33-43 monoamine oxidase B Homo sapiens 47-66 32682215-6 2020 Previous studies have shown that safinamide, a monoamine oxidase-B (MAOB) inhibitor, can function as a neuroprotective agent and inhibit the neurodegenerative process especially in Parkinson"s disease but its impact on other neurodegenerative processes and drug-induced neurotoxicity remain unclear. safinamide 33-43 monoamine oxidase B Homo sapiens 68-72 32682215-7 2020 Although there is some evidence that BDNF / TrkB / PGC-1alpha-UCP-2 signaling pathway and mitochondrial UCP-2 mediated safinamide induced neuroprotection but it"s exact and precise mechanism of action and neuroprotective effects in neurodegenerative disorder and the protective properties against methamphetamine induced neurodegeneration and the role of BDNF / TrkB / PGC-1alpha signaling pathway and role of mitochondrial UCP-2 in this process have not yet been clarified. safinamide 119-129 brain derived neurotrophic factor Homo sapiens 37-41 32682215-7 2020 Although there is some evidence that BDNF / TrkB / PGC-1alpha-UCP-2 signaling pathway and mitochondrial UCP-2 mediated safinamide induced neuroprotection but it"s exact and precise mechanism of action and neuroprotective effects in neurodegenerative disorder and the protective properties against methamphetamine induced neurodegeneration and the role of BDNF / TrkB / PGC-1alpha signaling pathway and role of mitochondrial UCP-2 in this process have not yet been clarified. safinamide 119-129 uncoupling protein 2 Homo sapiens 104-109 32682215-7 2020 Although there is some evidence that BDNF / TrkB / PGC-1alpha-UCP-2 signaling pathway and mitochondrial UCP-2 mediated safinamide induced neuroprotection but it"s exact and precise mechanism of action and neuroprotective effects in neurodegenerative disorder and the protective properties against methamphetamine induced neurodegeneration and the role of BDNF / TrkB / PGC-1alpha signaling pathway and role of mitochondrial UCP-2 in this process have not yet been clarified. safinamide 119-129 uncoupling protein 2 Homo sapiens 104-109 32613602-9 2020 Transwell assay showed safinamide prevented OGD/R-induced hyperpermeability and the reduction of occludin and ZO-1. safinamide 23-33 tight junction protein 1 Mus musculus 110-114 32613602-10 2020 Moreover, safinamide treatment suppressed OGD/R-caused induction of metalloproteinase 2 (MMP-2) and 9 (MMP-9). safinamide 10-20 matrix metallopeptidase 2 Mus musculus 89-101 32613602-10 2020 Moreover, safinamide treatment suppressed OGD/R-caused induction of metalloproteinase 2 (MMP-2) and 9 (MMP-9). safinamide 10-20 matrix metallopeptidase 9 Mus musculus 103-108 32673884-1 2020 INTRODUCTION: Safinamide, a selective, reversible monoamine oxidase B inhibitor with a sodium channel inhibitory effect, improves symptoms in advanced Parkinson"s disease (PD). safinamide 14-24 monoamine oxidase B Homo sapiens 50-69 32205118-6 2020 Using patch-clamp, we showed that safinamide reversibly inhibited sodium currents in HEK293T cells transfected with hNav1.4. safinamide 34-44 sodium voltage-gated channel alpha subunit 4 Homo sapiens 116-123 32648512-4 2020 The pharmacological profile of safinamide includes reversible monoamine oxidase B inhibition and modulation of voltage-dependent sodium- and calcium channels with consecutive decline of glutamate release. safinamide 31-41 monoamine oxidase B Homo sapiens 62-81 32681474-1 2021 Safinamide (SF) is a third-generation monoamine-oxidase-B inhibitor that proved efficacy as add-on to levodopa in fluctuating Parkinson"s disease (PD) patients. safinamide 0-10 monoamine oxidase B Homo sapiens 38-57 32681474-1 2021 Safinamide (SF) is a third-generation monoamine-oxidase-B inhibitor that proved efficacy as add-on to levodopa in fluctuating Parkinson"s disease (PD) patients. safinamide 12-14 monoamine oxidase B Homo sapiens 38-57 32205118-9 2020 The p.F1586C mutation in hNav1.4 greatly impaired safinamide inhibition, suggesting that the drug binds to the local anesthetic receptor site in the channel pore. safinamide 50-60 sodium voltage-gated channel alpha subunit 4 Homo sapiens 25-32 32086070-9 2020 MAO-B inhibitors safinamide and rasagiline differ in their abilities to inhibit depolarization-evoked glutamate release in the basal ganglia of parkinsonian rats. safinamide 17-27 monoamine oxidase B Rattus norvegicus 0-5 32446176-1 2020 INTRODUCTION: Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson"s disease (PD) as an adjunct to l-DOPA. safinamide 14-24 monoamine oxidase B Homo sapiens 55-74 32446176-1 2020 INTRODUCTION: Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson"s disease (PD) as an adjunct to l-DOPA. safinamide 14-24 monoamine oxidase B Homo sapiens 76-81 30341696-6 2018 Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors. safinamide 58-68 monoamine oxidase B Homo sapiens 24-29 32612042-4 2020 Safinamide is a novel, selective, and reversible inhibitor of monoamine oxidase B expected to increase dopamine levels in the brain and improve the symptoms of Parkinson"s disease. safinamide 0-10 monoamine oxidase B Homo sapiens 62-81 30160213-5 2019 In contrast, safinamide is a reversible MAOB inhibitor, and also inhibits voltage- sensitive sodium channels and glutamate release. safinamide 13-23 monoamine oxidase B Homo sapiens 40-44 30160213-6 2019 Safinamide is the prototype of a new generation of multi-active MAOB inhibitors, which includes the antiepileptic drug, zonisamide. safinamide 0-10 monoamine oxidase B Homo sapiens 64-68 30160213-9 2019 Among all antiparkinsonian agents, MAOB inhibitors are those with the greatest neuroprotective potential because of inhibition of dopamine metabolism, induction of neurotrophic factors, and, in the case of safinamide, inhibition of glutamate release. safinamide 206-216 monoamine oxidase B Homo sapiens 35-39 30919054-6 2019 RESULTS: The computational modelling studies identified a binding site for all the tau tracers on MAO-B; this was the same site as that for safinamide. safinamide 140-150 microtubule associated protein tau Homo sapiens 83-86 30919054-6 2019 RESULTS: The computational modelling studies identified a binding site for all the tau tracers on MAO-B; this was the same site as that for safinamide. safinamide 140-150 monoamine oxidase B Homo sapiens 98-103 30919054-7 2019 The binding affinity and free energy of binding for the tau tracers to MAO-B was substantial and in a similar range to those for safinamide. safinamide 129-139 microtubule associated protein tau Homo sapiens 56-59 30919054-7 2019 The binding affinity and free energy of binding for the tau tracers to MAO-B was substantial and in a similar range to those for safinamide. safinamide 129-139 monoamine oxidase B Homo sapiens 71-76 30341696-6 2018 Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors. safinamide 58-68 monoamine oxidase A Homo sapiens 169-174 30142650-1 2018 AIM: Safinamide (Xadago ) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson"s Disease (PD). safinamide 5-15 monoamine oxidase B Homo sapiens 56-61 30142650-1 2018 AIM: Safinamide (Xadago ) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson"s Disease (PD). safinamide 17-23 monoamine oxidase B Homo sapiens 56-61 29130466-2 2017 Safinamide, a new drug that has MAO-B inhibition and antiglutamatergic effects through inhibition of sodium channels, has shown efficacy for the treatment of fluctuations at doses of 50-100 mg/day. safinamide 0-10 monoamine oxidase B Homo sapiens 32-37 30154729-0 2018 Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients. safinamide 84-94 monoamine oxidase B Mus musculus 54-73 30153669-10 2018 The greatest reductions in pain were found with safinamide (Standardized mean difference = -4.83, 95% CI [-5.07 to -4.59], p < 0.0001), followed by cannabinoids and opioids, multidisciplinary team care, catechol-O-methyltransferase inhibitors, and electrical and Chinese therapies. safinamide 48-58 catechol-O-methyltransferase Homo sapiens 203-231 29760163-1 2018 Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson"s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson"s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor. safinamide 0-10 monoamine oxidase B Homo sapiens 40-59 29760163-1 2018 Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson"s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson"s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor. safinamide 0-10 monoamine oxidase B Homo sapiens 61-66 29760163-1 2018 Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson"s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson"s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor. safinamide 0-10 monoamine oxidase B Homo sapiens 374-379 29542008-2 2018 Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms. safinamide 0-10 monoamine oxidase B Homo sapiens 74-79 29339106-2 2018 Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. safinamide 99-109 monoamine oxidase B Homo sapiens 113-132 29339106-2 2018 Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. safinamide 99-109 monoamine oxidase B Homo sapiens 134-139 29464559-3 2018 Currently, the treatment of Parkinson"s disease involves the use of selective MAO B inhibitors such as rasagiline and safinamide. safinamide 118-128 monoamine oxidase B Homo sapiens 78-83 28682929-6 2017 Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. safinamide 26-36 monoamine oxidase B Homo sapiens 50-69 29018297-0 2017 Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson"s Disease. safinamide 0-6 monoamine oxidase B Homo sapiens 23-42 29018297-0 2017 Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson"s Disease. safinamide 8-18 monoamine oxidase B Homo sapiens 23-42 29018297-1 2017 Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson"s disease. safinamide 0-6 monoamine oxidase B Homo sapiens 23-42 29018297-1 2017 Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson"s disease. safinamide 8-18 monoamine oxidase B Homo sapiens 23-42 28682929-6 2017 Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. safinamide 26-36 monoamine oxidase B Homo sapiens 117-136 28682929-9 2017 In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide. safinamide 263-273 monoamine oxidase A Homo sapiens 112-131 28150570-2 2017 Four process-related impurities (Imp-B, Imp-C, Imp-D, and Imp-E) were found in the SAFM bulk drug. safinamide 83-87 inosine monophosphate dehydrogenase 1 Homo sapiens 47-52 28777756-2 2017 Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels. safinamide 0-10 monoamine oxidase B Homo sapiens 143-162 28537214-4 2017 Areas covered: This invited review suggests safinamide as an ideal compound for therapy of Parkinson"s disease, as its pharmacological profile includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and abnormal glutamate release. safinamide 44-54 monoamine oxidase B Homo sapiens 163-182 27855360-5 2017 Since some of the 3-benzyloxy-beta-nitrostyrene analogues possess potencies that are comparable to that of the reversible inhibitor, safinamide (IC50 = 0.080 muM), it may be concluded that this class may be promising leads for the development of reversible and selective MAO-B inhibitors, that may be useful for the management of Parkinson"s disease. safinamide 133-143 monoamine oxidase B Homo sapiens 271-276 27665574-3 2017 The pharmacological profile of safinamide includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent Na+ channels, modulation of Ca2+ channels, and inhibition of glutamate release. safinamide 31-41 monoamine oxidase B Homo sapiens 62-81 28110399-1 2017 Safinamide (Xadago ) is an orally active, selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) properties. safinamide 0-10 monoamine oxidase B Homo sapiens 64-83 28110399-1 2017 Safinamide (Xadago ) is an orally active, selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) properties. safinamide 12-18 monoamine oxidase B Homo sapiens 64-83 28777756-2 2017 Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels. safinamide 0-10 monoamine oxidase B Homo sapiens 164-169 28777756-8 2017 CONCLUSION: The favorable effect of safinamide on mood may be explained by the improvement in wearing off and by its modulation of glutamatergic hyperactivity and reversible MAO-B inhibition. safinamide 36-46 monoamine oxidase B Homo sapiens 174-179 27536120-6 2016 Therefore, safinamide is an ideal candidate for treatment of patients with PD, since its pharmacological profile includes reversible monoamine oxidase-B inhibition, blockade of voltage-dependent sodium channels, modulation of calcium channels, and inhibition of glutamate release. safinamide 11-21 monoamine oxidase B Homo sapiens 133-152 27803666-5 2016 The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clinically in treatment of Parkinson"s disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious. safinamide 176-186 monoamine oxidase B Homo sapiens 31-36 27803666-5 2016 The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clinically in treatment of Parkinson"s disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious. safinamide 176-186 monoamine oxidase B Homo sapiens 159-164 26300398-7 2016 Rasagiline, a monoamine oxidase B inhibitor, and lamotrigine, a sodium channel blocking drug, also protected dopaminergic neurons, indicating that safinamide may act by either or both mechanisms. safinamide 147-157 monoamine oxidase B Rattus norvegicus 14-33 26744740-3 2015 Ideal candidates for the balance of these neurotransmitter deficits are compounds like safinamide with broad mechanisms of action such as reversible monoamine oxidase type B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release. safinamide 87-97 monoamine oxidase B Homo sapiens 149-173 26917951-3 2016 SAF inhibits monoamine oxidase B and dopamine reuptake and glutamate release, blocks voltage-dependent sodium channels, and modulates calcium channels. safinamide 0-3 monoamine oxidase B Homo sapiens 13-32 26849427-1 2016 Safinamide (brand name Xadago , Zambon S.p.A) is a third-generation reversible MAO-B inhibitor, which also blocks sodium voltage-sensitive channels and modulates stimulated release of glutamate. safinamide 0-10 monoamine oxidase B Homo sapiens 79-84 25342080-8 2014 Promising results include the extension of L-dopa action without inducing LID of the novel monoamine oxidase B- and glutamate-release inhibitor safinamide; however, this had no obvious effect on existing LID. safinamide 144-154 monoamine oxidase B Homo sapiens 91-110 25711470-5 2015 of BPEI or safinamide to normal mice, the MAO-B activity in the brain was reduced by up to 90.6% or 82.4% at 1.0 hr. safinamide 11-21 monoamine oxidase B Mus musculus 42-47 26293004-6 2015 Positive results were also obtained with a new monoamine oxidase B (MAO-B) inhibitor (safinamide) and a catechol-O-methyltransferase COMT inhibitor (opicapone). safinamide 86-96 monoamine oxidase B Homo sapiens 68-73 26164425-3 2015 Safinamide is an investigational MAO-B inhibitor with non-dopaminergic properties that may provide advantages over its predecessors. safinamide 0-10 monoamine oxidase B Homo sapiens 33-38 24053341-3 2013 Safinamide has a unique pharmacological profile, which combines modulation of dopamine metabolism by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity. safinamide 0-10 monoamine oxidase B Homo sapiens 129-148 24950010-4 2014 We will also review several investigational treatments that have shown promise for the treatment of early Parkinson"s disease, including a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits MAO-B, dopamine uptake and glutamate and pardoprunox which is a 5HT-1A agonist and a partial dopamine agonist. safinamide 204-214 monoamine oxidase B Homo sapiens 230-235 24950010-4 2014 We will also review several investigational treatments that have shown promise for the treatment of early Parkinson"s disease, including a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits MAO-B, dopamine uptake and glutamate and pardoprunox which is a 5HT-1A agonist and a partial dopamine agonist. safinamide 204-214 5-hydroxytryptamine receptor 1A Homo sapiens 294-300 23518709-4 2013 Safinamide is currently in phase III development for use in Parkinson"s disease based on its inhibition of monoamine oxidase B, but the drug is also a potent state-dependent inhibitor of sodium channels. safinamide 0-10 monoamine oxidase B Rattus norvegicus 107-126 22133327-5 2011 A third MAO-B inhibitor (safinamide), which also combines additional non-dopaminergic properties of potential benefit to Parkinson"s disease, is currently under development in phase III clinical trials as adjuvant therapy to either a dopamine agonist or levodopa. safinamide 25-35 monoamine oxidase B Homo sapiens 8-13 23097240-2 2012 Ketoconazole was applied as a potent prototypic inhibitor of cytochrome CYP3A4, to determine the role of CYP3A4 in the metabolic clearance of safinamide. safinamide 142-152 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 23097240-8 2012 Overall, the study shows that CYP3A4 plays a minor role in the metabolism of safinamide in vivo. safinamide 77-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 23097240-9 2012 Therefore, safinamide can be administered together with potent CYP3A4 inhibitors without any requirement for dose adjustment. safinamide 11-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 27186120-3 2012 Currently under investigation for use in the treatment of PD, safinamide has multiple modes of action including monoamine oxidase B inhibition. safinamide 62-72 monoamine oxidase B Homo sapiens 112-131 23360954-2 2013 Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. safinamide 0-10 monoamine oxidase B Homo sapiens 16-35 22948897-5 2012 This study confirms that safinamide is a highly selective monoamine oxidase-B inhibitor, even at supratherapeutic doses, and suggests that it can be administered without tyramine-related dietary restrictions. safinamide 25-35 monoamine oxidase B Homo sapiens 58-77 20522954-0 2010 Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. safinamide 18-28 monoamine oxidase B Homo sapiens 70-89 22039878-7 2011 In particular, safinamide, a MAO B selective inhibitor in clinical trials for Parkinson"s disease, is neuroprotective by blocking the voltage-dependent Na+ and Ca2+ channels and the Ca2+-mediated glutamate release processes. safinamide 15-25 monoamine oxidase B Homo sapiens 29-34 21850574-11 2011 Safinamide, which inhibits monoamine oxidase (MAO)-B, does not affect oral tyramine metabolism mediated mostly by the intestinal MAO-A. safinamide 0-10 monoamine oxidase B Homo sapiens 27-52 20707760-5 2010 WHAT THE READER WILL GAIN: The reader will gain an understanding of safinamide and its mechanisms of action, including reversible MAOB inhibition and reduced dopamine reuptake with antiglutamatergic effects, and how it may potentially provide improvement of PD motor symptoms with an antidyskinetic effect through its effect on glutamate release. safinamide 68-78 monoamine oxidase B Homo sapiens 130-134 20522954-1 2010 Two polymorphs of safinamide {systematic name: (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide}, C(17)H(19)FN(2)O(2), a potent selective and reversible monoamine oxidase B (MAO-B) inhibitor, are described. safinamide 18-28 monoamine oxidase B Homo sapiens 158-177 20522954-1 2010 Two polymorphs of safinamide {systematic name: (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide}, C(17)H(19)FN(2)O(2), a potent selective and reversible monoamine oxidase B (MAO-B) inhibitor, are described. safinamide 18-28 monoamine oxidase B Homo sapiens 179-184 20522954-1 2010 Two polymorphs of safinamide {systematic name: (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide}, C(17)H(19)FN(2)O(2), a potent selective and reversible monoamine oxidase B (MAO-B) inhibitor, are described. safinamide 47-100 monoamine oxidase B Homo sapiens 158-177 20522954-1 2010 Two polymorphs of safinamide {systematic name: (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide}, C(17)H(19)FN(2)O(2), a potent selective and reversible monoamine oxidase B (MAO-B) inhibitor, are described. safinamide 47-100 monoamine oxidase B Homo sapiens 179-184 17824599-1 2007 Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity. safinamide 0-10 monoamine oxidase B Homo sapiens 267-286 18041937-9 2007 A third agent with MAO-B inhibition properties, safinamide, is in phase III development. safinamide 48-58 monoamine oxidase B Homo sapiens 19-24 18041937-10 2007 Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition. safinamide 27-37 monoamine oxidase B Homo sapiens 80-85 17915852-0 2007 Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. safinamide 89-99 monoamine oxidase B Homo sapiens 20-39 17915852-1 2007 Structures of human monoamine oxidase B (MAO B) in complex with safinamide and two coumarin derivatives, all sharing a common benzyloxy substituent, were determined by X-ray crystallography. safinamide 64-74 monoamine oxidase B Homo sapiens 20-39 17915852-1 2007 Structures of human monoamine oxidase B (MAO B) in complex with safinamide and two coumarin derivatives, all sharing a common benzyloxy substituent, were determined by X-ray crystallography. safinamide 64-74 monoamine oxidase B Homo sapiens 41-46 17824599-1 2007 Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity. safinamide 0-10 monoamine oxidase B Homo sapiens 288-293 17824599-1 2007 Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity. safinamide 0-10 monoamine oxidase A Homo sapiens 299-318 17824599-1 2007 Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity. safinamide 0-10 monoamine oxidase A Homo sapiens 320-325 17824599-3 2007 The highest MAO-B inhibitory potency (IC50 = 17 nM) and a good selectivity (SI = 2941) were displayed by (R)-21, a tetrahydroisoquinoline analogue of safinamide. safinamide 150-160 monoamine oxidase B Homo sapiens 12-17 17824599-5 2007 The significantly diverse MAO-B affinities of a number of R and S alpha-aminoamide enantiomers, including the two rigid analogues (21) of safinamide, indicated likely enantioselective interactions at the enzymatic binding sites. safinamide 138-148 monoamine oxidase B Homo sapiens 26-31 17199024-1 2007 Safinamide (SAF) ((S)-(+)-2-(4-(3-fluorobenzyloxy) benzylamino)propanamide) was initially synthetized by Farmitalia Carlo Erba (Italy). safinamide 0-10 thyroid hormone receptor alpha Homo sapiens 122-126 17199024-1 2007 Safinamide (SAF) ((S)-(+)-2-(4-(3-fluorobenzyloxy) benzylamino)propanamide) was initially synthetized by Farmitalia Carlo Erba (Italy). safinamide 12-15 thyroid hormone receptor alpha Homo sapiens 122-126 17260668-1 2006 This paper describes three methods to bioassay safinamide (CAS 133865-89-1) in biological fluids of humans and laboratory animals for pharmacokinetic, toxicokinetic and bioavailability studies. safinamide 47-57 BCAR1 scaffold protein, Cas family member Homo sapiens 59-62 17030737-0 2006 Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. safinamide 39-49 monoamine oxidase B Homo sapiens 104-109 11572661-1 2001 Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson"s disease (PD), pain and stroke [345222], [348351]. safinamide 0-10 monoamine oxidase B Homo sapiens 93-112 15082032-1 2004 OBJECTIVE: This paper describes the pharmacokinetics and the pharmacodynamics, in terms of monoamino oxidase type B (MAO-B) inhibition, in male healthy volunteers of orally administered safinamide, a new neuroprotectant that in experimental models has demonstrated strong anticonvulsant and antiparkinson activities. safinamide 186-196 monoamine oxidase B Homo sapiens 91-115 15082032-1 2004 OBJECTIVE: This paper describes the pharmacokinetics and the pharmacodynamics, in terms of monoamino oxidase type B (MAO-B) inhibition, in male healthy volunteers of orally administered safinamide, a new neuroprotectant that in experimental models has demonstrated strong anticonvulsant and antiparkinson activities. safinamide 186-196 monoamine oxidase B Homo sapiens 117-122 15082032-8 2004 Monoamine oxidase activity of both types A and B (MAO-A and MAO-B) was determined in plasma at different times (MAO-B) and correlated to safinamide levels, or in urine (MAO-A). safinamide 137-147 monoamine oxidase B Homo sapiens 60-65 15082032-12 2004 The drug was cleared with a t(1/2) of about 22 h. Safinamide reversibly inhibited MAO-B enzyme. safinamide 50-60 monoamine oxidase B Homo sapiens 82-87 15563241-11 2004 Safinamide combines sodium and calcium channel modulatory activity with monoamine oxidase B inhibition. safinamide 0-10 monoamine oxidase B Homo sapiens 72-91 12897643-0 2003 Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. safinamide 67-77 monoamine oxidase B Homo sapiens 130-149 12897643-1 2003 Safinamide is a novel neuroprotectant combining sodium and calcium channel blocking properties with selective, reversible monoamine oxidase type B (MAO B) inhibition. safinamide 0-10 monoamine oxidase B Homo sapiens 122-146 12897643-1 2003 Safinamide is a novel neuroprotectant combining sodium and calcium channel blocking properties with selective, reversible monoamine oxidase type B (MAO B) inhibition. safinamide 0-10 monoamine oxidase B Homo sapiens 148-153 11572661-1 2001 Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson"s disease (PD), pain and stroke [345222], [348351]. safinamide 0-10 monoamine oxidase B Homo sapiens 114-118 9580576-1 1998 PNU-151774E [(S)-(+)-2-(4-(3-fluorobenzyloxy) benzylamino) propanamide, methanesulfonate] is a structurally novel anticonvulsant having Na+ channel-blocking and glutamate release-inhibiting properties, as well as being a MAOB inhibitor. safinamide 0-11 monoamine oxidase B Rattus norvegicus 221-225 34871839-4 2022 In vitro biological evaluations revealed that compound D5 was the most potent, selective MAO-B inhibitor (IC50 = 0.019 muM, MAO-A/MAO-B selectivity index = 2440), which was 10-fold than that of miracle drug safinamide (IC50 = 0.163 muM, MAO-A/MAO-B selectivity index = 172). safinamide 207-217 monoamine oxidase B Rattus norvegicus 89-94 7699569-1 1994 The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. safinamide 52-103 monoamine oxidase A Rattus norvegicus 108-125 7699569-1 1994 The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. safinamide 52-103 monoamine oxidase A Rattus norvegicus 127-130 7699569-2 1994 In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10(-7) M for MAO-B and higher than 10(-5) M for MAO-A. safinamide 10-19 monoamine oxidase B Rattus norvegicus 84-89 7699569-2 1994 In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10(-7) M for MAO-B and higher than 10(-5) M for MAO-A. safinamide 10-19 monoamine oxidase B Rattus norvegicus 127-132 7699569-2 1994 In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10(-7) M for MAO-B and higher than 10(-5) M for MAO-A. safinamide 10-19 monoamine oxidase A Rattus norvegicus 162-167 34990933-4 2022 Both series yielded low micromolar selective inhibitors of human MAO-B, namely indole 2 (IC50 = 12.63 +- 1.21 microM) and piperazine 39 (IC50 = 19.25 +- 4.89 microM), which is comparable to selective MAO-B inhibitor isatin (IC50 = 6.10 +- 2.81 microM), yet less potent in comparison to safinamide (IC50 = 0.029 +- 0.002 microM). safinamide 286-296 monoamine oxidase B Homo sapiens 65-70 34597253-2 2022 AREAS COVERED: : Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. safinamide 17-27 monoamine oxidase B Homo sapiens 65-84 34871839-4 2022 In vitro biological evaluations revealed that compound D5 was the most potent, selective MAO-B inhibitor (IC50 = 0.019 muM, MAO-A/MAO-B selectivity index = 2440), which was 10-fold than that of miracle drug safinamide (IC50 = 0.163 muM, MAO-A/MAO-B selectivity index = 172). safinamide 207-217 monoamine oxidase A Rattus norvegicus 237-242 34871839-4 2022 In vitro biological evaluations revealed that compound D5 was the most potent, selective MAO-B inhibitor (IC50 = 0.019 muM, MAO-A/MAO-B selectivity index = 2440), which was 10-fold than that of miracle drug safinamide (IC50 = 0.163 muM, MAO-A/MAO-B selectivity index = 172). safinamide 207-217 monoamine oxidase B Rattus norvegicus 243-248 34142645-1 2021 Besides the inhibition of monoamine-oxidase-B, high-dose safinamide (100 mg) also blocks voltage-gated Na+ and Ca++ channels and inhibits glutamate release at overactive synapses. safinamide 57-67 monoamine oxidase B Homo sapiens 26-45 34784871-11 2021 Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses. safinamide 35-45 monoamine oxidase B Homo sapiens 3-22 34856803-5 2022 SM in Xadago in the high-humidity environment undergoes phase transformation to the P21 form which can be easily reversed just by heating up to 80 C. For the commercial form of the API, there is also a reversible thermal transformation observed between Z" = 1 Z" = 3 crystallographic forms in the 0-20 C temperature range. safinamide 0-2 H3 histone pseudogene 16 Homo sapiens 84-87 34856803-5 2022 SM in Xadago in the high-humidity environment undergoes phase transformation to the P21 form which can be easily reversed just by heating up to 80 C. For the commercial form of the API, there is also a reversible thermal transformation observed between Z" = 1 Z" = 3 crystallographic forms in the 0-20 C temperature range. safinamide 6-12 H3 histone pseudogene 16 Homo sapiens 84-87 34970960-6 2021 Safinamide, a reversible MAO-B inhibitor that utilises both dopaminergic and non-dopaminergic mechanisms, was recently approved by the European Medicines Agency (EMA) (2015) and U.S. FDA (2017) as an add-on therapy for patients with mid- or late-stage Parkinson"s disease. safinamide 0-10 monoamine oxidase B Homo sapiens 25-30 34453687-12 2021 Further, safinamide significantly (p < 0.05) induced the expressions of autophagic proteins (Beclin-1 and LC3-II) in cortex. safinamide 9-19 beclin 1 Rattus norvegicus 93-101 34453687-12 2021 Further, safinamide significantly (p < 0.05) induced the expressions of autophagic proteins (Beclin-1 and LC3-II) in cortex. safinamide 9-19 annexin A3 Rattus norvegicus 106-109 34823038-2 2022 We previously showed that short-term treatment with safinamide, a monoamine oxidase type-B inhibitor with anti-glutamatergic properties, improves abnormally enhanced short-interval intracortical facilitation (SICF) in PD patients. safinamide 52-62 monoamine oxidase B Homo sapiens 66-90 34373044-10 2021 In addition, after safinamide, the mean UPDRS-II and III scores decreased, while PDSS-2 score indicating an improvement in both motor symptoms and nocturnal sleep features. safinamide 19-29 decaprenyl diphosphate synthase subunit 2 Homo sapiens 81-87 34390968-0 2021 Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson"s disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies. safinamide 30-40 monoamine oxidase B Homo sapiens 79-85 34390968-3 2021 Herein, a structural optimization strategy for safinamide (a well-known second generation hMAO-B inhibitor) afforded a series of thirty-six safinamide-derived new analogs (4aa-bj). safinamide 47-57 monoamine oxidase B Homo sapiens 90-96 34390968-3 2021 Herein, a structural optimization strategy for safinamide (a well-known second generation hMAO-B inhibitor) afforded a series of thirty-six safinamide-derived new analogs (4aa-bj). safinamide 140-150 monoamine oxidase B Homo sapiens 90-96 35107654-4 2022 For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. safinamide 24-34 monoamine oxidase B Homo sapiens 8-13 35596745-9 2022 A high concentration of flortaucipir (IC50 of 1.3 muM) was found to block binding of the MAO-B ligand safinamide to MAO-B on microsomes suggesting that, at micromolar concentrations, flortaucipir weakly binds to MAO-B in vitro. safinamide 102-112 monoamine oxidase B Homo sapiens 89-94 35596745-9 2022 A high concentration of flortaucipir (IC50 of 1.3 muM) was found to block binding of the MAO-B ligand safinamide to MAO-B on microsomes suggesting that, at micromolar concentrations, flortaucipir weakly binds to MAO-B in vitro. safinamide 102-112 monoamine oxidase B Homo sapiens 116-121 35190544-1 2022 Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. safinamide 0-10 monoamine oxidase B Homo sapiens 45-50 34162132-0 2021 Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-kappaB signaling. safinamide 0-10 toll like receptor 4 Homo sapiens 96-100 34162132-0 2021 Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-kappaB signaling. safinamide 0-10 nuclear factor kappa B subunit 1 Homo sapiens 101-110 34162132-5 2021 Safinamide is a selective and reversible monoamine oxidase B (MAOB) inhibitor that has been used for the treatment of Parkinson"s disease. safinamide 0-10 monoamine oxidase B Homo sapiens 41-60 34162132-5 2021 Safinamide is a selective and reversible monoamine oxidase B (MAOB) inhibitor that has been used for the treatment of Parkinson"s disease. safinamide 0-10 monoamine oxidase B Homo sapiens 62-66 34162132-7 2021 Our results show that safinamide inhibited the expression of pro-inflammatory cytokines such as IL-1alpha, TNF-alpha, and IL-6. safinamide 22-32 interleukin 1 alpha Homo sapiens 96-105 34162132-7 2021 Our results show that safinamide inhibited the expression of pro-inflammatory cytokines such as IL-1alpha, TNF-alpha, and IL-6. safinamide 22-32 tumor necrosis factor Homo sapiens 107-116 34162132-7 2021 Our results show that safinamide inhibited the expression of pro-inflammatory cytokines such as IL-1alpha, TNF-alpha, and IL-6. safinamide 22-32 interleukin 6 Homo sapiens 122-126 34162132-8 2021 Furthermore, safinamide suppressed the production of CXCL1 and CCL2, thereby preventing leukocyte migration. safinamide 13-23 C-X-C motif chemokine ligand 1 Homo sapiens 53-58 34162132-8 2021 Furthermore, safinamide suppressed the production of CXCL1 and CCL2, thereby preventing leukocyte migration. safinamide 13-23 C-C motif chemokine ligand 2 Homo sapiens 63-67 34162132-9 2021 In addition, safinamide reduced iNOS-derived NO, COX-2-derived PGE2, MMP-2, and MMP-9. safinamide 13-23 matrix metallopeptidase 2 Homo sapiens 69-74 34162132-9 2021 In addition, safinamide reduced iNOS-derived NO, COX-2-derived PGE2, MMP-2, and MMP-9. safinamide 13-23 matrix metallopeptidase 9 Homo sapiens 80-85 34162132-10 2021 Importantly, the functions of safinamide mentioned above were found to be dependent on its inhibitory effect on the TLR4/NF-kappaB signaling pathway. safinamide 30-40 toll like receptor 4 Homo sapiens 116-120 34162132-10 2021 Importantly, the functions of safinamide mentioned above were found to be dependent on its inhibitory effect on the TLR4/NF-kappaB signaling pathway. safinamide 30-40 nuclear factor kappa B subunit 1 Homo sapiens 121-130 35001806-0 2022 Safinamide protects against amyloid beta (Abeta)-induced oxidative stress and cellular senescence in M17 neuronal cells. safinamide 0-10 amyloid beta precursor protein Homo sapiens 28-40 35001806-0 2022 Safinamide protects against amyloid beta (Abeta)-induced oxidative stress and cellular senescence in M17 neuronal cells. safinamide 0-10 amyloid beta precursor protein Homo sapiens 42-47 35001806-2 2022 Safinamide is one of the clinically prescribed monoamine oxidase B (MAOB) inhibitors. safinamide 0-10 monoamine oxidase B Homo sapiens 47-66 35001806-2 2022 Safinamide is one of the clinically prescribed monoamine oxidase B (MAOB) inhibitors. safinamide 0-10 monoamine oxidase B Homo sapiens 68-72 35001806-9 2022 Further, we show that safinamide treatment resulted in decreased mRNA and protein expressions of p21 and plasminogen activator inhibitor-1 (PAI-1). safinamide 22-32 cyclin dependent kinase inhibitor 1A Homo sapiens 97-100 35001806-9 2022 Further, we show that safinamide treatment resulted in decreased mRNA and protein expressions of p21 and plasminogen activator inhibitor-1 (PAI-1). safinamide 22-32 serpin family E member 1 Homo sapiens 105-138 35001806-9 2022 Further, we show that safinamide treatment resulted in decreased mRNA and protein expressions of p21 and plasminogen activator inhibitor-1 (PAI-1). safinamide 22-32 serpin family E member 1 Homo sapiens 140-145 35001806-10 2022 Moreover, silencing of Sirtuin1 (SIRT1) abolished the effects of safinamide on the mRNA levels of p21 and PAI-1, as well as SA-beta-gal-positive cells in Abeta1-42 oligomers-induced M17 cells. safinamide 65-75 sirtuin 1 Homo sapiens 23-31 35001806-10 2022 Moreover, silencing of Sirtuin1 (SIRT1) abolished the effects of safinamide on the mRNA levels of p21 and PAI-1, as well as SA-beta-gal-positive cells in Abeta1-42 oligomers-induced M17 cells. safinamide 65-75 sirtuin 1 Homo sapiens 33-38 35001806-10 2022 Moreover, silencing of Sirtuin1 (SIRT1) abolished the effects of safinamide on the mRNA levels of p21 and PAI-1, as well as SA-beta-gal-positive cells in Abeta1-42 oligomers-induced M17 cells. safinamide 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 98-101 35001806-10 2022 Moreover, silencing of Sirtuin1 (SIRT1) abolished the effects of safinamide on the mRNA levels of p21 and PAI-1, as well as SA-beta-gal-positive cells in Abeta1-42 oligomers-induced M17 cells. safinamide 65-75 serpin family E member 1 Homo sapiens 106-111 35001806-11 2022 In conclusion, we reveal that safinamide exerted a protective function on M17 cells from Abeta1-42 oligomers induction-caused oxidative stress and cellular senescence through SIRT1 signaling. safinamide 30-40 sirtuin 1 Homo sapiens 175-180